Establishment and clinical application of a highly sensitive enzyme immunoassay for determination of N-acetyl-seryl-aspartyl-lysyl-proline

Journal of Peptide Science

Volumn 18, Issue 4, 2012, Pages 276-281

  Suzuki, Yosuke ^a   Itoh, Hiroki ^a   Katagiri, Fumihiko ^b   Sato, Fuminori ^c   Kawasaki, Kanako ^a   Sato, Yuhki ^a   Mimata, Hiromitsu ^c   Takeyama, Masaharu ^a  

^a OITA UNIVERSITY HOSPITAL   (Japan)

^b TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES   (Japan)

^c OITA UNIVERSITY   (Japan)

Author keywords

Ac SDKP; AcSDKP; Chronic renal failure; Clinical application; Enzyme immunoassay; N acetyl seryl aspartyl lysyl proline

Indexed keywords

4 METHYLUMBELLIFERYL BETA DEXTRO GALACTOPYRANOSIDE; ANTIGEN; BETA GALACTOSIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLUORESCENT DYE; GLYCINE GAMMA SERYLASPARTYLLYSYLPROLINE; IMMUNOGLOBULIN G ANTIBODY; SERASPENIDE; UNCLASSIFIED DRUG;

ADULT; AFFINITY LABELING; AGED; AMINO ACID BLOOD LEVEL; ARTICLE; BLOOD SAMPLING; CALIBRATION; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION COEFFICIENT; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; ENZYME ANALYSIS; ENZYME IMMUNOASSAY; ENZYME INHIBITION; FEMALE; HEMODIALYSIS; HISTOPATHOLOGY; HUMAN; HYPERTENSION; IMMUNOREACTIVITY; LIMIT OF QUANTITATION; MALE; PATIENT MONITORING; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; ANTIBODY SPECIFICITY; ANTICOAGULANTS; BETA-GALACTOSIDASE; BIOLOGICAL MARKERS; CALIBRATION; CASE-CONTROL STUDIES; CIRCADIAN RHYTHM; EDETIC ACID; FEMALE; HEPARIN; HUMANS; IMMUNE SERA; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; OLIGOPEPTIDES; PROTEIN STABILITY; REFERENCE STANDARDS; RENAL INSUFFICIENCY, CHRONIC; SENSITIVITY AND SPECIFICITY;

ORYCTOLAGUS CUNICULUS;

EID: 84858862383     PISSN: 10752617     EISSN: 10991387     Source Type: Journal    
DOI: 10.1002/psc.2400     Document Type: Article

References (22)

1. Guigon M, Bonnet D, Lemoine FM, Kobari L, Permentier C, Mary JY, Najman A. Inhibition of human bone marrow progenitors by the synthetic tetrapeptide AcSDKP. Exp. Hematol. 1990; 18: 1112-1115.
2. Cavasin MA, Rhaleb NE, Yang XP, Carretero OA. Prolyl oligopeptidase is involved in release of the antifibrotic peptide Ac-SDKP. Hypertension 2004; 43: 1140-1145.
3. Bonnet D, Lemoine FM, Pontvert-Delucq S, Baillou C, Najman A, Guigon M. Direct and reversible inhibitory effect of the tetrapeptide acetyl-N-Ser-Asp-Lys-Pro (Seraspenide) on the growth of human CD34+ subpopulations in response to growth factors. Blood 1993; 82: 3307-3314.
4. Wdzieczak-Bakala J, Fache MP, Lenfant M, Frindel E, Sainteny F. AcSDKP, an inhibitor of CFU-S proliferation, is synthesized in mice under steady-state conditions and secreted by bone marrow in long-term culture. Leukemia 1990; 4: 235-237.
5. Pradelles P, Frobert Y, Créminon C, Liozon E, Massé A, Frindel E. Negative regulator of pluripotent hematopoietic stem cell proliferation in human white blood cells and plasma as analysed by enzyme immunoassay. Biochem. Biophys. Res. Commun. 1990; 170: 986-993.
6. Iwamoto N, Xano HJ, Yoshioka T, Shiraga H, Nitta K, Muraki T, Ito K. Acetyl-seryl-aspartyl-lysyl-proline is a novel natural cell cycle regulator of renal cells. Life Sci. 2000; 66: PL221-226.
7. Rhaleb NE, Peng H, Yang XP, Liu YH, Mehta D, Ezan E, Carretero OA. Long-term effect of N-acetyl-seryl-aspartyl-lysyl-proline on left ventricular collagen deposition in rats with 2-kidney, 1-clip hypertension. Circulation 2001; 103: 3136-3141.
8. Lenfant M, Wdzieczak-Bakala J, Guittet E, Prome JC, Sotty D, Frindel E. Inhibitor of hematopoietic pluripotent stem cell proliferation: purification and determination of its structure. Proc. Natl. Acad. Sci. USA 1989; 86: 779-782.
9. Pradelles P, Frobert Y, Cre'minon C, Ivonine H, Frindel E. Distribution of a negative regulator of haematopoietic stem cell proliferation (AcSDKP) and thymosin β4 in mouse tissues. FEBS Lett. 1991; 289: 171-175.
10. Rieger KJ, Saez-Servent N, Papet MP, Wdzieczak-Bakala J, Morgat JL, Thierry J, Voelter W, Lenfant M. Involvement of human plasma angiotensin I-converting enzyme in the degradation of the haemoregulatory peptide N-acetyl-seryl-aspartyl-lysyl-proline. Biochem. J. 1993; 296: 373-378.
11. Rousseau A, Michaud A, Chauvet MT, Lenfant M, Corvol P. The hemoregulatory peptide N-acetyl-Ser-Asp-Lys-Pro is a natural and specific substrate of the N-terminal active site of human angiotensin-converting enzyme. J. Biol. Chem. 1995; 270: 3656-3661.
12. Azizi M, Ezan E, Reny JL, Wdzieczak-Bakala - J, Gerineau V, Me'nard J. Renal and metabolic clearance of AcSDKP during ACE inhibition in humans. Hypertension 1999; 33: 879-886.
13. Azizi M, Rousseau A, Ezan E, Guyene TT, Michelet S, Grognet J-M, Lenfant M, Corvol P, Me'nard J. Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-proline. J. Clin. Invest. 1996; 97: 839-844.
14. Azizi M, Ezan E, Nicolet L, Grognet JM, Menard J. High plasma level of N-acetyl-seryl-aspartyl-lysyl-proline: a new marker of chronic angiotensin-converting enzyme inhibition. Hypertension 1997; 30: 1015-1019.
15. van der Meer P, Lipsic E, Westenbrink BD, van de Wal RM, Schoemaker RG, Vellenga E, van Veldhuisen DJ, Voors AA, van Gilst WH. Levels of hematopoiesis inhibitor N-acetyl-seryl-aspartyl-lysyl-proline partially explain the occurrence of anemia in heart failure. Circulation 2005; 112: 1743-1747.
16. Le Meur Y, Aldigier JC, Praloran V. Is plasma Ac-SDKP level a reliable marker of chronic angiotensin-converting enzyme inhibition in hypertensive patients? Hypertension 1998; 31: 1201-1202.
17. Le Meur Y, Lorgeot V, Comte L, Szelag JC, Aldigier JC, Leroux-Robert C, Praloran V. Plasma levels and metabolism of AcSDKP in patients with chronic renal failure: relationship with erythropoietin requirements. Am. J. Kidney Dis. 2001; 38: 510-517.
18. Junot C, Pruvost A, Créminon C, Grognet JM, Benech H, Ezan E. Characterization of immunoreactive acetyl-Ser-Asp-Lys-Pro in human plasma and urine by liquid chromatography-electrospray mass spectrometry. J. Chromatogr. B Biomed. Sci. Appl. 2001; 752: 69-75.
19. Inoue K, Ikemura A, Tsuruta Y, Watanabe K, Tsutsumiuchi K, Hino T, Oka H. Quantification of N-acetyl-seryl-aspartyl-lysyl-proline in hemodialysis patients administered angiotensin-converting enzyme inhibitors by stable isotope dilution liquid chromatography-tandem mass spectrometry. J. Pharm. Biomed. Anal. 2011; 54: 765-771.
20. Tai HH, Chey WY. Development of radioimmunoassay for motilin. Anal. Biochem. 1978; 87: 350-358.
21. Kitagawa T, Shimozono T, Aikawa T, Yoshida T, Nishimura H. Preparation and characterization of hetero-bifunctional cross-linking reagents for protein modifications. Chem. Pharm. Bull. 1981; 29: 1130-1135.
22. Ezan E, Carde P, Le Kerneau J, Ardouin T, Thomas F, Isnard F, Deschamps de Paillette E, Grognet JM. Pharmcokinetics in healthy volunteers and patients of NAc-SDKP (seraspenide), a negative regulator of hematopoiesis. Drug Metab. Dispos. 1994; 22: 843-848.